WASHINGTON, DC - Today, Energy and Commerce Committee Chairman Greg Walden (R-OR) and Subcommittee on Health Chairman Michael C. Burgess, M.D. (R-TX) released the following statement after President Donald Trump signed S. 2465, the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018, as well as S. 3029, the PREEMIE Reauthorization Act of 2018, into law yesterday evening.
“These bills signed into law last night represent another step in the right direction in improving maternal health outcomes and making meaningful strides to guaranteeing patients with complex blood disorders receive the quality care and treatment they deserve," said Chairman Walden and #SubHealth Chairman Burgess. “There is always more work to be done to advance public health, but reauthorizing these important programs ensures that the innovations and advancements that they promote will continue to serve the people who need them most in the years to come."
